High Point, North Carolina (June 15, 2015) vTv Therapeutics LLC (vTv), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates, today announced it has filed a registration statement on Form S-1 with the U.S.
In a 6 Week Phase 2a Study, Treatment Showed Statistically Significant and Clinically Meaningful Reduction in A1c Levels High Point, North Carolina (June 4, 2015) vTv Therapeutics LLC announced today that it has initiated dosing of the AGATA study, a phase 2b clinical trial assessing the efficacy
Completed Phase 2 Trial Showed Positive Results Combating Alzheimer’s Disease High Point, North Carolina (May 19, 2015) vTv Therapeutics LLC (vTv) today announced enrollment of the first patients into STEADFAST (Single Trial Evaluating Alzheimer’s Disease Following Addition to Symptomatic Therapy),
High Point, North Carolina (March 5, 2015) TransTech Pharma, LLC today announced a global licensing agreement granting Calithera Biosciences, Inc. exclusive world-wide rights to research, develop and commercialize TransTech’s portfolio of hexokinase II inhibitors.
High Point, North Carolina (July 10, 2014) TransTech Pharma, LLC today announced that it has reached an agreement with the U.S. Food and Drug Administration Division of Neurology Products, under the Special Protocol Assessment (SPA) process, on the design of a single Phase 3 trial of TTP488 for the
High Point, North Carolina (April 15, 2014) TransTech Pharma, LLC (“TransTech”) announced today that effective March 28, 2014, Stephen L. Holcombe, who previously served as the Company’s Senior Vice President and Chief Financial Officer, has been appointed to serve as the President of TransTech and
High Point, North Carolina (August 14, 2013) TransTech Pharma Inc. announced today important clinical trial data for its new diabetes drug. TTP399, a novel, liver-selective glucokinase activator (GKA), demonstrated clinical evidence of normalizing HbA 1c without inducing hypoglycemia in type 2
High Point, North Carolina (July 1, 2013) TransTech Pharma Inc. announced today that it has successfully completed an End of Phase 2 meeting for TTP488 with the U.S. Food and Drug Administration (FDA). TTP488 is under development for the treatment of mild to moderate Alzheimer’s disease.
High Point, North Carolina (March 18, 2013) TransTech Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for TTP488, a new small-molecule chemical compound being developed for the treatment of Alzheimer’s disease.
High Point, North Carolina (November 1, 2012) TransTech Pharma, Inc., announced today that recruitment of patients for its recently initiated, multi-center Phase 2 clinical trial of TTP054 in type 2 diabetics, is exceeding expectations with initial top line results available in early 2013.